- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04553653
Improving Acute Hypertension Management Through Emergency Department Checklist
August 12, 2021 updated by: Johns Hopkins University
The investigators hypothesize that the implementation of a checklist in acute severe hypertension would result in improving short and long-term outcomes of patients with acute severe hypertension treated in the emergency department (ED).
The investigators hypothesize that in the short-term, a checklist would improve the diagnosis and management of end-organ damage as well as reduce the length of stay of acute severe hypertensive patients in the ED.
The investigators hypothesize that the checklist will result in better compliance with anti-hypertensive medications than without the checklist at six-month post-discharge.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Hypertension is a global public health issue and results in over 10 million deaths every year.
The disease affects one-third of people living in low- and middle-income countries (LMICs) and contributes to half of all productivity losses in LMICs due to non-communicable diseases.
Though hypertension often presents as a chronic asymptomatic illness, hypertension-related emergencies represent a significant burden to the health care system.
Acute severe hypertension [i.e., systolic blood pressure (SBP) ≥ 180 mmHg or diastolic blood pressure (DBP) ≥ 110 mmHg] make up to 5% of all emergency admission.
One-third of these patients present with end-organ damage; a condition called a hypertensive crisis.
More worrisome is the fact that a number of ED visits, as a result, severe acute hypertension and hypertensive crises have almost tripled between 2006 and 2013 in the US.
Treatment approaches to managing acute severe hypertension (~5% of ED patients) are largely unclear and only 6% of ED patients with acute severe hypertension receive appropriate work-up for the end-organ damage, indicating a huge care gap.
One approach, which has been used successfully in managing other complex and critical conditions, is the use of checklists.
Checklists are a listing of actions to be performed in a given clinical setting with the aim of improving adherence to standards, reducing errors and thus improving patient outcomes.
The investigators hypothesize that the use of a Checklist, if appropriately implemented, can lead to an improvement in the care of patients presenting with hypertensive crisis.
During this study, the investigators will measure the prevalence of acute severe hypertension and assess the current quality of care for these patients.
This will be followed by the development of a checklist for the management of the hypertensive crises in the ED.
The investigators will follow these patients to see the impact of the checklist on the quality of care and long-term outcomes.
Study Type
Interventional
Enrollment (Actual)
1161
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Karachi, Pakistan, 7440
- Aga Khan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults who visit the Aga Khan University Hospital Emergency Department with acute severe hypertension
- able to provide consent to participate
- Age >25 years of age
- Meeting the criteria of acute severe hypertension (SBP>180 and DBP>110).
Exclusion Criteria:
- Patients not providing consent or are unconscious are excluded from participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Baseline
Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
|
|
|
Experimental: Intervention arm
The intervention arm will be enrolled after the checklist implementation.
|
The checklist will be implemented and healthcare providers use the checklist to manage the patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in frequency of diagnosis of hypertensive emergency
Time Frame: Baseline and 6 months after checklist implementation
|
The frequency of correct diagnosis of hypertensive emergency in patients with severe hypertension with evidence of end-organ damage in the ED before and after the implementation of the checklist.
|
Baseline and 6 months after checklist implementation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the use of appropriate medications for treatment of hypertensive emergency
Time Frame: Baseline and 6 months after checklist implementation
|
We will measure the compliance with the hypertensive emergency treatment protocol before and after implementation of the checklist.
|
Baseline and 6 months after checklist implementation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compliance with chronic treatment of hypertension as assessed through a phone call
Time Frame: Up to 6 months post discharge from the emergency department
|
We will follow up our patients on phone to assess their compliance with the use of antihypertensive medications.
|
Up to 6 months post discharge from the emergency department
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Junaid A Razzak, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2019
Primary Completion (Actual)
April 30, 2021
Study Completion (Actual)
April 30, 2021
Study Registration Dates
First Submitted
September 11, 2020
First Submitted That Met QC Criteria
September 11, 2020
First Posted (Actual)
September 17, 2020
Study Record Updates
Last Update Posted (Actual)
August 13, 2021
Last Update Submitted That Met QC Criteria
August 12, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00195002
- 5R21TW011175-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on checklist
-
RWTH Aachen UniversityCompleted
-
Indonesia UniversityUnknownHypertensionIndonesia
-
University of IowaCompleted
-
Imperial College LondonActive, not recruiting
-
University Hospital, Basel, SwitzerlandCompletedElderly Internal Medicine Patients
-
Express CollaborativeKidSIM-ASPIRECompleted
-
West China HospitalCompletedEndovascular Therapy | Neurological ComplicationsChina
-
Ottawa Hospital Research InstituteCompletedAtrial Fibrillation | Atrial FlutterCanada
-
Rhode Island HospitalCompleted